Type 2 Diabetes | Current Treatment: Physician Insights | US | 2018


Biguanides and sulfonylureas are by far the most heavily prescribed type 2 diabetes (T2D) drug classes. However, several branded agents are jostling for position as second- and third-line treatment options. Availability of multiple effective therapies from several classes combined with variations in prescribed combinations of drugs, physician preference for specific insulin regimens, and the launch of biosimilar insulins create a challenging market for developers.

Questions Answered

  • How frequently are physicians prescribing combinations of T2D drugs, and which are their preferred combinations? Which factors drive or constrain physicians’ prescribing practices?
  • What is the current branded patient share of insulins such as Sanofi’s Lantus and Eli Lilly’s Humalog? What is the current branded patient share of GPL-1 receptor agonists such as Novo Nordisk’s Ozempic and Eli Lilly’s Trulicity? What are the anticipated changes in prescribing patterns over the next 12 months?
  • Which insulin regimens do physicians prefer to use in T2D? What percentage of T2D patients use an insulin pump versus a basal-bolus regimen?
  • What is the current market impact of Boehringer Ingelheim/Eli Lilly’s Basaglar on branded originator products?

Product Description

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that you can create specific messaging around these treatment dynamics to more effectively increase or defend your market position.

Markets Covered: United States

Primary Research Info

Type 2 Diabetes Current Treatment: Physician Insights is a primary market research study, evaluating physician self-reported prescribing and treatment practices for type 2 diabetes. E-mail invitations were sent to endocrinologists and PCPs to participate in an online survey. Fifty endocrinologists and 50 PCPs completed the survey, which took approximately 30 minutes to complete. Fieldwork occurred in July 2018. To qualify, respondents met the following screening criteria:

  • Board-certified in diabetes.
  • In practice for a minimum of 2 years and a maximum of 35 years.
  • Do not practice in Vermont.
  • More than 75% of professional time spent in clinical practice.

After meeting the screening criteria, respondents were directed to an online survey, and respondents were paid an honorarium for their participation. Statistical significance testing was done when appropriate, including anticipated versus current allocations, subgroups, and brands.

Key companies: Sanofi, Novo Nordisk, Boehringer Ingelheim, Eli Lilly, AstraZeneca, Janssen, Merck & Co.

Key drugs: metformin, Lantus, Levemir, Toujeo, Tresiba, Basaglar, NovoLog, Humalog, Apidra, Ozempic, Victoza, Trulicity, Januvia, Jardiance, Invokana, Farxiga.

Login to access report